亞太藥業(002370.SZ)：收到《行政處罰及市場禁入事先吿知書》
格隆匯 2 月 28日丨亞太藥業(002370.SZ)公佈，公司於2019年12月31日收到《中國證券監督管理委員會調查通知書》(浙證調查字2019427號)，因公司涉嫌信息披露違法違規，根據《中華人民共和國證券法》等有關規定，中國證券監督管理委員會(以下簡稱"中國證監會")決定對公司進行立案調查。
2021年2月26日，公司收到中國證券監督管理委員會浙江監管局下發的《行政處罰及市場禁入事先吿知書》(浙處罰字[2021]2號)。
根據當事人違法行為的事實、性質、情節，依據 2005 年《證券法》第一百九十三條第一款的規定，中國證監會浙江監管局擬決定：
1、對亞太藥業責令改正，給予警吿，並處以 60 萬元罰款；
2、對任軍、陳堯根給予警吿，並分別處以 30 萬元罰款；
3、對呂旭幸、何珍、沈依伊給予警吿，並分別處以 15 萬元罰款；
4、對孫黎明、胡寶坤、王麗雲、譚欽水給予警吿，並分別處以8 萬元罰款；
5、對鍾婉珍、平華標、陳樞青、姚先國、章勇堅、詹金彪、何大安、莫國萍、成華強、趙科學、王國賢給予警吿，並分別處以 3 萬元罰款。
此外，任軍、陳堯根的違法行為情節嚴重，依據 2005 年《證券法》第二百三十三條及《證券市場禁入規定》(證監會令第 115 號)第三條、第五條的規定，中國證監會浙江監管局擬對任軍、陳堯根分別採取 5 年證券市場禁入。
根據《中華人民共和國行政處罰法》第三十二條、第四十二條及《中國證券監督管理委員會行政處罰聽證規則》相關規定，就中國證監會浙江監管局擬對相關當事人實施的行政處罰及市場禁入，相關當事人享有陳述、申辯的權利，其中，亞太藥業、任軍、陳堯根、呂旭幸、何珍、沈依伊、孫黎明、胡寶坤、王麗雲、譚欽水並享有要求聽證的權利。相關當事人提出的事實、理由和證據，經中國證監會浙江監管局複核成立的，中國證監會浙江監管局將予以採納。如果相關當事人放棄陳述、申辯和聽證的權利，中國證監會浙江監管局將按照上述事實、理由和依據作出正式的行政處罰及市場禁入決定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
